Review Article
Inositols in the Treatment of Insulin-Mediated Diseases
Table 1
Clinical studies in which MYO or DCI supplementation has been evaluated for the treatment of disease associated to insulin resistance.
| Authors, year | Inositol isomers | Duration of treatment | Experimental models |
| Genazzani et al., 2008 [17] | MYO 2 gr | 12 weeks | PCOS | Genazzani et al., 2012 [18] | MYO 2 gr | 8 weeks | PCOS | Gerli et al., 2007 [19] | MYO 4 gr | 14 weeks | PCOS | Artini et al., 2013 [20] | MYO 2 gr | 12 weeks | PCOS | Iuorno et al., 2002 [21] | DCI 600 mg | 6 to 8 weeks | PCOS | Laganà et al., 2015 [22] | DCI 1 gr | 6 months | PCOS | Giordano et al., 2011 [23] | MYO 2 gr BID | 6 months | Postmenopausal women with metabolic syndrome | Santamaria et al., 2012 [24] | MYO 2 gr BID | 12 months | Postmenopausal women with metabolic syndrome | Corrado et al., 2011 [25] | MYO 4 gr | 8 weeks | Pregnant women with gestational diabetes | D’Anna et al., 2013 [26] | MYO 2 gr | 6 months | Pregnant women with a family history of type 2 diabetes |
|
|
Note. MYO: myo-inositol; DCI: D-chiroinositol.
|